Carlo Barone

Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

Chiara Cremolini, Daniele Rossini, Emanuela Dell’Aquila et al. · JAMA Oncology · 2018 · 420 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

Magdolna Dank, J. Załuski, Carlo Barone et al. · Annals of Oncology · 2008 · 343 citations · Full text

Medicine, Oncology, Pharmacology +13

Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab

Andrea Sartore‐Bianchi, Mauro Moroni, Silvio Veronese et al. · Journal of Clinical Oncology · 2007 · 337 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

Massimo Aglietta, Carlo Barone, M. B. Sawyer et al. · Annals of Oncology · 2014 · 221 citations · Full text

Medicine, Oncology, Pharmacology +12

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial

Denis Soulières, Sandrine Faivre, Éva Remenár et al. · The Lancet Oncology · 2017 · 219 citations

Medicine, Oncology, Pharmacotherapy +11